ClinicalTrials.gg
CompletedNCT06991634Updated Nov 17, 2025

A Study to Evaluate the Pharmacokinetics and Safety of Azvudine Tablets in Healthy Adult Subjects and Healthy Elderly Subjects

A Phase 1 interventional study of Azvudine tablets in Healthy, sponsored by Henan Genuine Biotech Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-17.

Sponsored by Henan Genuine Biotech Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 1 month after the study started (first participant enrolled Apr 2023, registered May 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

Azvudine (FNC), a nucleoside reverse transcriptase inhibitor, make itself a better candidate to be co-formulated in other anti-HIV therapies, thus to improve patient's compliance. FNC is a broad-spectrum RNA virus inhibitor that inhibits the novel coronavirus RNA-dependent RNA polymerase (RdRp). This is an open, parallel design clinical study to evaluate the pharmacokinetics and safety of Azvudine tablets in healthy adult and elderly subjects in single and multiple doses. The study is divided into two stages. In the first stage, after a single oral administration of 5 mg of Azvudine tablets, biological sample collection and safety examination were performed. After completing the first phase of the test, the subjects can enter the second phase of the test after a 3-day washout period, and received oral administration of 5 mg Azvudine tablets once a day for 7 consecutive days, biological samples were collected and safety tests were performed.

02

Conditions studied

  • Healthy

Keywords

  • Azvudine
  • Pharmacokinetics
  • Safety
03

In context

Lead sponsor

Henan Genuine Biotech Co., Ltd. is the lead sponsor of 13 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Healthy adult subjects :

  1. Age ≥ 18 years old and ≤ 45 years old, regardless of gender ;
  2. ( BMI ) in the range of 19.0-26.0 ( including the critical value ) ( BMI = weight ( kg ) / height 2 ( m2 ) ), male weight should be ≥ 50.0kg, female weight should be ≥ 45.0kg ;

Healthy elderly subjects :

  1. Age ≥ 60 years old and ≤ 85 years old, regardless of gender ;
  2. Body mass index ( BMI ) in the range of 18.0-35.0 ( including the critical value ) ( BMI = weight ( kg ) / height 2 ( m2 ) ) ;
  3. Before the test, the existing disease if any was in a stable state and the treatment intervention or medication had no effect on this study.

Healthy adult subjects and healthy elderly subjects :

  1. Patients who had no plan to become pregnant within 2 weeks before screening and 3 months after the end of the trial and agreed to take effective non-drug during the trial ;
  2. Understand and sign the .

Exclusion criteria

Exclusion Criteria:

Healthy adult subjects:

  1. The medical history, physical examination, laboratory items before the test, and the test-related examinations and test abnormalities have clinical significance, and the clinical research doctor judges that they are not eligible;
  2. Subjects who have any history of prescription drugs, over-the-counter drugs, Chinese herbal medicines and healthcare products within 14 days before screening;

Healthy elderly subjects:

  1. History or evidence of cardiovascular disease prior to screening: uncontrolled hypertension (SBP ≥ 170 mmHg and/or DBP ≥ 105 mmHg without antihypertensive therapy; SBP>160mmHg and/or DBP>100 mmHg with antihypertensive therapy), orthostatic hypotension, severe arrhythmias, heart failure, Adams-Stokes syndrome, unstable angina, history of myocardial infarction within 6 months prior to screening, tachycardia/bradycardia requiring medication, II-III degree atrioventricular block (excluding patients with pacemakers), or interval ≥ 450ms(Fridericia method);
  2. The (MMSE) score results judged by the investigator are not suitable for this study;

Healthy adult subjects and healthy elderly subjects:

  1. Allergic constitution, history of drug or food allergy, especially allergic to any ingredient in this product and accessories;
  2. Patients with severe infection, trauma, or major surgery 4 weeks before screening, or who are scheduled to undergo surgery during the study;
  3. Fever within 3 days before screening;
  4. Those with serious diseases such as cerebral infarction and cancer in the past, except for benign diseases (such as liver cyst, renal cyst, fatty liver, etc.) based on chest radiograph and color Doppler ultrasound that do not need treatment;
  5. Those who have participated in other clinical trials within 3 months before screening;
  6. Drinking excessive amounts of tea, coffee and/or drinks rich in caffeine, xanthine and alcohol (more than 8 cups, 1 cup = 250mL) every day within 3 months before screening;
  7. Smoking history within 12 months before screening (smoking number ≥ 5 cigarettes per day);
  8. Those with a history of alcohol abuse within 12 months before screening (drinking ≥ 14 units of alcohol per week: 1 unit = 285mL of beer, or 25mL of spirits, or 150mL of wine) or those with a positive alcohol breath test (detection value> 0mg/100mL) before entering the group;
  9. Those with a history of drug abuse within 12 months prior to screening or those who tested positive for addictive substances before entering the group;
  10. Blood loss or blood donation ≥ 200mL within 8 weeks before screening (except for female physiological blood loss);
  11. Pregnant and lactating women;
  12. Those who cannot tolerate venipuncture blood collection and/or those who have a history of bleeding, acupuncture and/or blood collection vascular conditions are poor;
  13. Those who have received the new coronavirus vaccine within 14 days before screening or other vaccines within 3 months before screening, or plan to receive the vaccine during the trial period;
  14. The investigator considered it unsuitable to enter this study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Healthy adult subjects

    Drug: Azvudine tablets

  • Experimental
    Healthy elderly subjects

    Drug: Azvudine tablets

Interventions

  • Phase I: oral administration of 5 mg of Azvudine tablets on an empty stomach, single dose, 5 mg per dose. Phase II: oral administration of 5 mg of Azvudine tablets once a day on an empty stomach, 5 mg once a day, for 7 consecutive days.

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax) of Azvudine

    Time frame: Up to 36 hours post-dose.

  2. Pharmacokinetics (PK): Area Under the Plasma Concentration Curve (AUC) of Azvudine

    Time frame: Up to 36 hours post-dose.

  3. Pharmacokinetics (PK): Time to Maximum Plasma Concentration (Tmax) of Azvudine

    Time frame: Up to 36 hours post-dose.

  4. Pharmacokinetics (PK): Elimination Half-life (T1/2) of Azvudine

    Time frame: Up to 36 hours post-dose.

Secondary outcomes

  1. Occurrence of Adverse Events

    Time frame: From enrollment to the end of the study on Day 12.

07

Study locations

1 site
  • Tianjin Fifth Central Hospital
    Tianjin, Tianjin Municipality, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2023 to primary completion in Apr 2023, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2025
First posted
May 28, 2025
StartActual
Apr 8, 2023
Primary completionActual
Apr 27, 2023
CompletionActual
Jun 20, 2023
Last update
Nov 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06991634
Lead sponsor
Henan Genuine Biotech Co., Ltd.
Responsible party
Sponsor
First posted
May 28, 2025
Start date
Apr 8, 2023
Primary completion
Apr 27, 2023
Completion
Jun 20, 2023
Last update
Nov 17, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Azvudine

Start the discussion